Axxcess Wealth Management LLC Buys 2,285 Shares of Novo Nordisk A/S (NYSE:NVO)

Axxcess Wealth Management LLC grew its stake in Novo Nordisk A/S (NYSE:NVO) by 8.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,748 shares of the company’s stock after purchasing an additional 2,285 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,559,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Folketrygdfondet boosted its holdings in Novo Nordisk A/S by 0.5% during the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock worth $765,917,000 after acquiring an additional 40,313 shares during the last quarter. Sustainable Growth Advisers LP lifted its position in shares of Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after purchasing an additional 1,021,498 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Novo Nordisk A/S during the fourth quarter worth about $404,910,000. WCM Investment Management LLC grew its position in Novo Nordisk A/S by 1.0% in the 4th quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company’s stock worth $345,588,000 after purchasing an additional 40,475 shares in the last quarter. Finally, Amundi increased its stake in Novo Nordisk A/S by 26.4% in the 4th quarter. Amundi now owns 3,311,456 shares of the company’s stock valued at $283,615,000 after buying an additional 692,567 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $80.95 on Wednesday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market cap of $363.28 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $73.80 and a 52 week high of $148.15. The firm’s 50-day simple moving average is $83.81 and its two-hundred day simple moving average is $101.98.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 13th. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.